On April 29, in order to further understand the needs of its members, better serve them, and promote exchanges and cooperation, Zhang Mengfan, Secretary-General of Sichuan International Medical Exchange& Promotion Association (SCIMEA) led a team accompanied by Liu Miaomiao, the Chinese regional representative of Translational Research Center for Medical lnnovation (TRI) from Kobe, Japan and general manager of Snet Science and Technology Co., Ltd., went to Chengdu Easton Biopharmaceuticals Co., Ltd. for a survey. Wang Ying, president and general manager of Chengdu Easton Biopharmaceuticals Co., Ltd., Chen Zenggui, deputy general manager of the Marketing Department, and Chen Hong, general manager of the R & D Center, etc., as well as other leaders and workers from the company warmly received the team led by SCIMEA.
During the discussion and exchange, Deputy General Manager Chen Zenggui introduced e Chengdu Easton Biopharmaceuticals Co., Ltd. (hereinafter referred to as Easton) in detail. Since its establishment in 2009, Easton has always adhered to its original mission of "Centering on Patients and Shining for Human Health", insisted on its innovative development strategies, kept its differentiated and professional development strategies, achieved sustained, rapid and healthy development, and constantly demonstrated its enterprise value as well as social value of "Nourishing All, Helping from East". During its development, Easton has achieved countless excellent results by upholding innovation, breakthroughs, teamwork, and scientific management. In 2019, Easton made outstanding achievements with awards of "Top 100 Sichuan Enterprises of Technology Innovation Capacity 2019","Top 20 Sichuan Enterprises with the Most Potential for Technological Innovation and Development 2019","Top 100 Sichuan Enterprises in Technology Innovation R & D Investment 2019","Top 100 Sichuan Enterprises in Invention Patent Ownership 2019","Pharmaceutical Industry Benchmark Enterprise at the 70th Anniversary of the Founding of P. R. C", etc. Just a few days ago, the technology center of Easton was recognized as the National Enterprise Technology Center.
General Manager Liu Miaomiao introduced the Translational Research Center for Medical innovation (TRI) of Cobe, Japan. TRI is a semi-official organization under the direct administration of Pharmaceuticals and Medical Devices Evaluation Center in Japan. It consists of a team of more than 300 experts, and the chairman of the center is Professor Tasuku Honjo (Kyoto University), PD-1 inventor and 2018 Nobel Prize winner. Former Professor Fukushima of Kyoto University serves as the director of the center. The center manages thousands of projects mainly initiated by researchers from top universities or R & D companies in Japan, especially various regenerative medical products such as stem cell therapies and biomaterials, immunotherapies, gene therapies, and clinical trials of new drugs. More than 400 of them have entered clinical trials. Relying on TRI, Snet provides support, investment, achievement transformation and technological transfer for R & D of new drugs, medical devices, and regenerative medicine, bringing excellent medical research results from China and Japan to medical researchers in both countries, providing a communication platform, promoting advanced medical technological achievement transformation, and helping build Chengdu into a biomedical achievement transformation center in Asia.
Finally, she gave a high recognition of the forward-looking, pioneering, and extensive technological innovation of Easton, and said at the meeting that there is huge room for cooperation with Easton and she looked forward to the full cooperation of both parties.
Secretary-General Zhang Mengfan highly praised the excellent achievements of Easton. Under the leadership of President Wang Ying, the company focuses on the core strength of science and technology, the team management efficiency, and the differentiated development, and thus it has become a high-quality and high-tech pharmaceutical enterprise with considerable strength, positive attitude and social responsibility integrating the full industrial chain of “research, production and sales” of drugs. The Secretary-General also introduced the functions, membership services and work overview of SCIMEA. President Wang Ying showed his high recognition of the association’s rich and practical membership service functions, its aid for bottleneck breakthrough of its members, its efforts on interaction among its members, and its promotion of international cooperation. He said that the company will conduct in-depth exchanges and cooperation with SCIMEA, further enhance the multi-disciplinary interactive cooperation with TRI, and coordinate its development through international cooperation, scientific research improvement, brand promotion, talent introduction, etc. All parties shall work together to build a quality association in western China “with a positive attitude and social responsibility” and an influential brand association nationwide and internationally.
Later, the survey team visited the pharmaceutical workshop and new drug R & D center of Easton.
This visit has deepened the communication between SCIMEA and its member, strengthened the understanding among its members, and provided a solid foundation and typical case in serving members with higher quality, performing its functions, and promoting cooperation.
